# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Franklin D. Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET002-SYN-TD
- Date: 1944-06-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathaniel Brooks, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month heart failure and blood pressure review. **S**

## History of present illness

Mr. Roosevelt returns for his three-month review. He propels his wheelchair on level ground without stopping and is breathless only on long ramps. He sleeps on one pillow and has had no leg swelling for several weeks. His home weights have held at 83 to 84 kg for a month, and his home blood pressures run in the 120s over 70s. He felt more energetic within a few weeks of the iron infusions and is working full days again. He has had no lightheadedness on transfers, no breast tenderness on spironolactone, and no muscle aches on atorvastatin. He has not smoked since April, cravings are now rare, and he asks to stop the patch. **S**

| Element | Detail |
|---|---|
| Interval change | Level ground without stopping; breathless only on long ramps; one pillow; no edema |
| Weight log | Stable at 83 to 84 kg for a month |
| Home blood pressure | 120s over 70s |
| Medication tolerance | No lightheadedness, breast tenderness, or muscle aches |
| Function | Working full days again |
| Tobacco | No cigarettes since April; rare cravings |
| NYHA class | II |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | More energy since the iron infusions; no fever |
| Cardiovascular | Negative | No chest pain, palpitations, orthopnea, or leg swelling |
| Respiratory | Positive | Breathless only on long ramps; morning cough fading |
| Genitourinary | Negative | No dysuria or genital itching |
| Neurological | Negative | No lightheadedness on transfers |
| Musculoskeletal | Negative | No muscle aches or cramps |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |

7 systems reviewed. **S**

## Current medications

- Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice daily **S**
- Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with food **S**
- Spironolactone 25 mg oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 70 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 83 kg; BMI 23.5 kg/m². All vital signs are synthetic.

NT-proBNP: 980 pg/mL (high); Sodium: 138 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 1.24 mg/dL; eGFR: 66 mL/min/1.73 m²; Glucose: 96 mg/dL; Hemoglobin: 13.6 g/dL; Ferritin: 236 ng/mL; Transferrin saturation: 27%; KCCQ-12 overall summary: 64; PHQ-2: 0. All results are synthetic.

## Change since baseline

- NT-proBNP: 2850 pg/mL (high) at baseline, 980 pg/mL (high) at this visit **S**
- Sodium: 137 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Creatinine: 1.18 mg/dL at baseline, 1.24 mg/dL at this visit **S**
- eGFR: 70 mL/min/1.73 m² at baseline, 66 mL/min/1.73 m² at this visit **S**
- Glucose: 104 mg/dL (high) at baseline, 96 mg/dL at this visit **S**
- Hemoglobin: 12.6 g/dL (low) at baseline, 13.6 g/dL at this visit **S**
- Ferritin: 48 ng/mL at baseline, 236 ng/mL at this visit **S**
- Transferrin saturation: 16% (low) at baseline, 27% at this visit **S**
- KCCQ-12 overall summary: 38 at baseline, 64 at this visit **S**
- PHQ-2: 1 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and energetic; weight 83 kg on the wheelchair scale |
| Neck | Jugular venous pressure 6 cm |
| Lungs | Clear |
| Heart | Regular rhythm, rate 70; no S3 |
| Chest | No breast enlargement or tenderness |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with reduced ejection fraction, euvolemic** (I50.22). No congestion on examination and a stable weight; NYHA class II. NT-proBNP has fallen from 2850 to 980 pg/mL and the KCCQ-12 has risen from 38 to 64, meeting his goal. Potassium 4.6 mmol/L and creatinine 1.24 mg/dL (eGFR 66) on sacubitril/valsartan 49/51 mg and spironolactone. **S**
   - Increase carvedilol to 12.5 mg twice daily with food; heart rate 70 and blood pressure 128/78 allow it.
   - Stop daily furosemide, since he is euvolemic with a stable weight; call for a weight gain of more than 1 kg in a day or 2 kg in a week, or for returning leg swelling.
   - Keep sacubitril/valsartan at 49/51 mg for now, to make one change at a time while carvedilol rises and furosemide stops; reconsider at the six-month review.
   - Continue spironolactone and empagliflozin.
   - Basic metabolic panel in one to two weeks, because potassium can rise once the loop diuretic stops.
   - Referral to cardiac rehabilitation with seated, upper-body exercise training.
   - Repeat echocardiogram at the six-month review.
2. **Iron deficiency in heart failure, repleted** (D50.9). Hemoglobin 13.6 g/dL, ferritin 236 ng/mL, and transferrin saturation 27 percent after two intravenous iron doses: repleted, and the anemia has resolved. **S**
   - No further iron now; iron studies yearly.
3. **Hypertensive heart disease** (I11.0). Blood pressure 128/78 mmHg, below the 130/80 target, with home readings in the 120s over 70s. **S**
   - Keep it below target through the six-month review.
4. **Nicotine dependence, cigarettes, in early remission** (F17.210). Abstinent since April, meeting his goal, after a 13-week nicotine patch course. **S**
   - Stop the patch.
   - Relapse plan: restart a patch with a short-acting nicotine product at once if he smokes again.
5. **Hyperlipidemia** (E78.5). Atorvastatin 40 mg taken every day without muscle symptoms. The confirming lipid panel has not been drawn. **S**
   - Lipid panel with the six-month laboratory tests.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | 1 to 2 weeks after starting or changing sacubitril/valsartan, spironolactone, empagliflozin, or a diuretic; every 3 to 6 months when stable | Completed today | Potassium 4.6, creatinine 1.24 mg/dL, eGFR 66. This is the first panel since sacubitril/valsartan was increased and spironolactone started eleven weeks ago |
| Laboratory | Basic metabolic panel 1 to 2 weeks after the April changes | Once, after titrating sacubitril/valsartan and starting spironolactone | Deferred | Not drawn in the window: the panel planned for the second iron infusion was not done, a deviation from the protocol. Today's potassium and kidney function are normal, so no harm resulted. Corrective action: each medication change now comes with a dated laboratory appointment booked before he leaves |
| Laboratory | Basic metabolic panel after stopping furosemide | 1 to 2 weeks after a diuretic change | Due | Furosemide stops today while he continues spironolactone and sacubitril/valsartan, which can raise potassium |
| Laboratory | NT-proBNP | Selectively in outpatient follow-up | Completed today | 980 pg/mL, down from 2850; informs decongestion and prognosis, not used to titrate therapy |
| Laboratory | Hemoglobin, ferritin, and transferrin saturation | 6 to 8 weeks after intravenous iron; then yearly | Completed today | Hemoglobin 13.6, ferritin 236, transferrin saturation 27 percent: repleted. Drawn ten weeks after the second dose, two weeks after the window, as planned in April; repletion is confirmed, so the delay caused no harm |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin | Deferred | Not drawn in the window, which closed last week, and not on today's order, a deviation from the lipid protocol. He takes every dose and has no muscle symptoms, and a three-month delay in confirming the response carries little risk. Corrective action: added to the six-month laboratory order |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit; every 1 to 2 weeks during titration | Completed today | Euvolemic at 83 kg |
| Survey | NYHA functional class | Every visit | Completed today | Class II |
| Survey | KCCQ-12 | Every 3 to 6 months | Completed today | 64, up 26 points from baseline |
| Survey | Depression screen (PHQ-2) | Periodically | Completed today | Score 0 |
| Imaging | Transthoracic echocardiogram | 3 to 6 months after therapy is optimized | Due | Planned for the six-month review, three months after today's carvedilol step |
| Imaging | 12-lead ECG | At initial evaluation; repeat with device consideration | Due | Still not on file (deviation recorded in April); needed before the device decision at the six-month review |
| Referral | Cardiac rehabilitation | Ejection fraction 35 percent or less, NYHA II to IV, after 6 weeks of optimal therapy | Referred | Eligible: ejection fraction 30 percent, NYHA II, three months of therapy, no hospital stay. Referred to a program that adapts training for wheelchair users with arm ergometry and resistance bands |
| Medication safety | Spironolactone and carvedilol safety | Each visit while titrating | Completed today | Potassium 4.6; no breast tenderness; heart rate 70 with no lightheadedness |
| Medication safety | Tobacco use and cessation treatment | Every visit | Completed today | Abstinent since April; patch course complete |
| Laboratory | HbA1c, urine albumin-creatinine ratio, and TSH | HbA1c and urine albumin yearly; TSH at diagnosis | Up to date | Drawn at diagnosis; the urine albumin test is repeated at the six-month review |
| Self-management | Home blood pressure and daily weight log; low-sodium diet | Every visit | Completed today | Log reviewed; weight-gain action plan given for the stop of furosemide |

## Goal progress

- Lower blood pressure below 130/80 by the six-month review. In progress; target 1944-09-25. **S**
- Improve the KCCQ-12 overall summary score by at least 20 points by the three-month review. Outcome by 1944-06-26: KCCQ-12 rose from 38 to 64. **S**
- Stop smoking by the three-month review. Outcome by 1944-06-26: No cigarettes since April; nicotine patch course completed. **S**
- Reach the highest tolerated doses of guideline-directed therapy by the six-month review. In progress; target 1944-09-25. **S**

## Medication changes

- Stopped: Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with food **S**
- Started: Carvedilol 12.5 mg oral tablet, one tablet by mouth twice daily with food **S**
- Stopped: Furosemide 20 mg oral tablet, one tablet by mouth daily **S**
- Stopped: Nicotine 21 mg/24 hr transdermal patch, apply one patch daily **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026), Aether Forge
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force

## Follow-up

- Basic metabolic panel in one to two weeks after stopping furosemide. Six-month heart failure review with an echocardiogram, laboratory tests including a lipid panel, and the KCCQ-12. **S**
- Next scheduled visit 1944-09-25: six-month heart failure review with repeat echocardiogram. **S**
